Cadila Pharma unveils antihistamine drug Bilastine in India
The Bilastine has an advantage over other molecules available in the category, as the faster onset of action, non-drowsy, cardiac safe. Cadila Pharmaceutical's product under the brand name Bilacad also ensures better safety and efficacy.
Ahmedabad: Cadila Pharmaceuticals Limited has recently announced the launch of Bilastine syrup (30 ml) and Bilastine tablets in the strength of 20mg. It is indicated that Bilastine, an antihistamine drug is used in the treatment of allergic rhinitis.
Bilastine is an antihistamine which addresses the current gap in the treatment of Allergic Rhinitis and meets the expectations of doctors to treat their allergic rhinitis patients. The Bilastine has an advantage over other molecules available in the category, as the faster onset of action, non-drowsy, cardiac safe. Cadila Pharmaceutical's product under the brand name Bilacad also ensures better safety and efficacy.
India has seen a growth in the number of cases of allergic rhinitis induced due to tobacco smoke, exposure to air pollutants, vehicular pollution, and other air pollution.
Moreover, as per a recent study published in Lung India, 65% of the Indian allergic rhinitis patients also suffer from Asthma. Improved control of nasal allergies can help gain better control on Asthma.
Cadila Pharmaceuticals Ltd. has recently concluded USFDA inspection successfully in February 2020.
Read also: Zydus Cadila gets USFDA nod to antihistamine Meclizine Hydrochloride Tablets
